High level of protection against COVID-19 after two doses of BNT162b2 vaccine in the working age population–first results from a cohort study in Southern Sweden
(2022) In Infectious Diseases 54(2). p.128-133- Abstract
Background: Vaccine effectiveness against COVID-19 needs to be assessed in diverse real-world population settings. Methods: A cohort study of 805,741 residents in Skåne county, Southern Sweden, aged 18–64 years, of whom 26,587 received at least one dose of the BNT162b2 vaccine. Incidence rates of COVID-19 were estimated in sex- and age-adjusted analysis and stratified in two-week periods with substantial community spread of the disease. Results: The estimated vaccine effectiveness in preventing infection ≥7 days after second dose was 86% (95% CI 72–94%) but only 42% (95% CI 14–63%) ≥14 days after a single dose. No difference in vaccine effectiveness was observed between females and males. Having a prior positive test was associated with... (More)
Background: Vaccine effectiveness against COVID-19 needs to be assessed in diverse real-world population settings. Methods: A cohort study of 805,741 residents in Skåne county, Southern Sweden, aged 18–64 years, of whom 26,587 received at least one dose of the BNT162b2 vaccine. Incidence rates of COVID-19 were estimated in sex- and age-adjusted analysis and stratified in two-week periods with substantial community spread of the disease. Results: The estimated vaccine effectiveness in preventing infection ≥7 days after second dose was 86% (95% CI 72–94%) but only 42% (95% CI 14–63%) ≥14 days after a single dose. No difference in vaccine effectiveness was observed between females and males. Having a prior positive test was associated with 91% (95% CI 85–94%) effectiveness against new infection among the unvaccinated. Conclusion: A satisfactory effectiveness of BNT162b2 after the second dose was suggested, but with possibly substantially lower effect before the second dose.
(Less)
- author
- Björk, Jonas LU ; Inghammar, Malin LU ; Moghaddassi, Mahnaz LU ; Rasmussen, Magnus LU ; Malmqvist, Ulf LU and Kahn, Fredrik LU
- organization
- publishing date
- 2022
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- COVID-19 testing, COVID-19 vaccines, SARS-CoV2, vaccine effectiveness
- in
- Infectious Diseases
- volume
- 54
- issue
- 2
- pages
- 128 - 133
- publisher
- Informa Healthcare
- external identifiers
-
- pmid:34586934
- scopus:85115992228
- ISSN
- 2374-4235
- DOI
- 10.1080/23744235.2021.1982144
- project
- Improved preparedness for future pandemics and other health crises through large-scale disease surveillance
- language
- English
- LU publication?
- yes
- additional info
- Publisher Copyright: © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
- id
- 77ac9b1b-93c6-4347-b00f-8654d190a9c9
- date added to LUP
- 2021-10-25 11:48:31
- date last changed
- 2024-04-20 13:55:03
@article{77ac9b1b-93c6-4347-b00f-8654d190a9c9, abstract = {{<p>Background: Vaccine effectiveness against COVID-19 needs to be assessed in diverse real-world population settings. Methods: A cohort study of 805,741 residents in Skåne county, Southern Sweden, aged 18–64 years, of whom 26,587 received at least one dose of the BNT162b2 vaccine. Incidence rates of COVID-19 were estimated in sex- and age-adjusted analysis and stratified in two-week periods with substantial community spread of the disease. Results: The estimated vaccine effectiveness in preventing infection ≥7 days after second dose was 86% (95% CI 72–94%) but only 42% (95% CI 14–63%) ≥14 days after a single dose. No difference in vaccine effectiveness was observed between females and males. Having a prior positive test was associated with 91% (95% CI 85–94%) effectiveness against new infection among the unvaccinated. Conclusion: A satisfactory effectiveness of BNT162b2 after the second dose was suggested, but with possibly substantially lower effect before the second dose.</p>}}, author = {{Björk, Jonas and Inghammar, Malin and Moghaddassi, Mahnaz and Rasmussen, Magnus and Malmqvist, Ulf and Kahn, Fredrik}}, issn = {{2374-4235}}, keywords = {{COVID-19 testing; COVID-19 vaccines; SARS-CoV2; vaccine effectiveness}}, language = {{eng}}, number = {{2}}, pages = {{128--133}}, publisher = {{Informa Healthcare}}, series = {{Infectious Diseases}}, title = {{High level of protection against COVID-19 after two doses of BNT162b2 vaccine in the working age population–first results from a cohort study in Southern Sweden}}, url = {{http://dx.doi.org/10.1080/23744235.2021.1982144}}, doi = {{10.1080/23744235.2021.1982144}}, volume = {{54}}, year = {{2022}}, }